[Clinical evaluation of neocarzinostatin in digestive system cancer. 1. Administration of neocarzinostatin in advanced and recurrent carcinoma of the stomach].
This study was designed to evaluate the most effective administration method of NCS for advanced carcinoma of the stomach, mainly nonresectable and/or recurrent cases which were collected by our cooperative study group. Nine hundred seventy six cases were available for clinical evaluation. Rate of the efficacy of NCS alone and combined with 5-FU was higher (P less than 0.1) in the cases administrated intravenously by drip infusion than in those by one shot injection method, and adverse effects were fewer in the former than in the latter cases. The rate of efficacy of NCS was higher in cases treated with 4,000 mu/day alone intermittently 2-3 times for a week than in those with 2,000 mu/day alone every day. The rate of clinical effect was higher in the cases treated with 4,000 mu of NCS combined with 50 mg of 5-FU intermittently than in those with 2,000 mu of NCS combined with 250 mg of 5-FU every day, especially 20.6% of the former cases given more than 50,000 mu of NCS were interpreted as clinically effective by Karnofsky's criteria of I-A over.
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy*; D009353:Zinostatin / Q000008:administration & dosage*
D000903:Antibiotics, Antineoplastic; D009353:Zinostatin; D005472:Fluorouracil